Hospira, Inc. and Subsidiaries | Pfizer | Illinois | state | 2007 | $404,000 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2014 | $403,872 | | tax credit/rebate |
Centocor Research & Development, Inc. | Johnson & Johnson | Pennsylvania | state | 2009 | $402,833 | | tax credit/rebate |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | local | 2011 | $402,482 | | tax credit/rebate; property tax abatement |
Doral/Pfizer | Pfizer | New York | local | 2015 | $402,469 | | tax credit/rebate |
Doral/Pfizer | Pfizer | New York | local | 2016 | $402,469 | | tax credit/rebate |
Shire Pharmaceuticals Inc. | Takeda Pharmaceutical | Pennsylvania | state | 2008 | $402,051 | | tax credit/rebate |
Abraxis BioScience | Bristol-Myers Squibb | Iowa | state | 2008 | $400,000 | | grant/loan hybrid program |
Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | Pennsylvania | state | | $400,000 | | grant |
C3i Incorporated | Merck | Pennsylvania | state | | $400,000 | | grant |
Novavax, Inc. | Novavax Inc. | Pennsylvania | state | | $400,000 | | grant |
Barr Laboratories, Inc. | Teva Pharmaceutical Industries | Virginia | state | 2008 | $400,000 | | grant |
OMEROS CORP | Omeros Corp. | Washington | state | 2014 | $398,897 | | tax credit/rebate |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2015 | $398,897 | | tax credit/rebate |
GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA | GlaxoSmithKline | Washington | state | 2006 | $397,686 | | tax credit/rebate |
MILLIPORE CORPORATION | Merck KGaA (EMD) | Missouri | state | 2011 | $397,131 | | tax credit/rebate |
Albany Molecular | Curia Inc. | New York | local | 2011 | $395,043 | | tax credit/rebate; property tax abatement |
LAX/Amneal Pharmaceuticals | Amneal Pharmaceuticals | New York | local | 2013 | $393,986 | | tax credit/rebate; property tax abatement |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2012 | $393,682 | | tax credit/rebate; property tax abatement |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2020 | $390,921 | | tax credit/rebate |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2019 | $390,739 | | tax credit/rebate |
AMRI Rensselaer, Inc. | Curia Inc. | New York | state | 2012 | $390,683 | | enterprise zone |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2021 | $390,427 | | tax credit/rebate |
CENTOCOR BIOLOGICS, LLC SERIES 2005 | Johnson & Johnson | Missouri | state | 2006 | $386,661 | | tax credit/rebate |
Idexx Laboratories, Inc. | IDEXX Laboratories | Maine | state | 2018 | $385,883 | | tax credit/rebate |
MacroGenics, Inc. | MacroGenics | Maryland | state | 2017 | $385,562 | | tax credit/rebate |
Novartis Pharmaceuticals Corp. | Novartis | North Carolina | state | 2019 | $385,031 | | tax credit/rebate |
Abbott Laboratories | Abbott Laboratories | Illinois | state | 2006 | $381,909 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2006 | $380,245 | | tax credit/rebate |
Abbott Laboratories | Abbott Laboratories | Illinois | state | 2005 | $378,187 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2005 | $375,100 | | tax credit/rebate |
Bausch & Lomb Incorporated | Bausch Health | New York | state | 2013 | $375,037 | | enterprise zone |
OSI Pharmaceuticals LLC | Astellas Pharma | New York | local | 2013 | $374,233 | | tax credit/rebate; property tax abatement |
Wyeth Holdings Corporation | Pfizer | North Carolina | state | 2010 | $373,801 | | tax credit/rebate |
Amneal Pharmaceutical of NY, LLC | Amneal Pharmaceuticals | New York | state | 2012 | $372,801 | | enterprise zone |
Novozymes North America, Inc. | Novo Holdings A/S | North Carolina | state | 2010 | $372,272 | | tax credit/rebate |
Forest Research Institute, Inc. | AbbVie | Pennsylvania | state | 2013 | $369,915 | | tax credit/rebate |
Nupathe, Inc. | Teva Pharmaceutical Industries | Pennsylvania | state | 2008 | $369,626 | | tax credit/rebate |
Gilead Sciences, Inc. | Gilead Sciences | North Carolina | state | 2010 | $367,742 | | tax credit/rebate |
Sanofi Pasteur Inc. (fka Aventis Pasteur Inc.) | Sanofi | Pennsylvania | state | 2008 | $363,760 | | tax credit/rebate |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New York | state | 2009 | $363,019 | | enterprise zone |
AMRI Rensselaer, Inc. | Curia Inc. | New York | state | 2011 | $363,000 | | enterprise zone |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2009 | $361,233 | | tax credit/rebate; property tax abatement |
Regeneron CSC Way Project | Regeneron Pharmaceuticals | New York | local | 2020 | $361,165 | | tax credit/rebate |
Regeneron 1 CSC Way Project | Regeneron Pharmaceuticals | New York | local | 2020 | $361,165 | | tax credit/rebate |
Doral/Pfizer | Pfizer | New York | local | 2011 | $360,540 | | tax credit/rebate; property tax abatement |
Forest Laboratories, Inc. and Forest Research | AbbVie | New Jersey | state | 1999 | $360,150 | | grant |
ABBOTT DIABETES CARE | Abbott Laboratories | California | state | 2007 | $359,454 | | training reimbursement |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2008 | $358,648 | | tax credit/rebate; property tax abatement |
Doral/Pfizer | Pfizer | New York | local | 2012 | $357,613 | | tax credit/rebate; property tax abatement |
Bristol Myers Squibb (Mr. Leon Squibb) | Bristol-Myers Squibb | New York | local | 2004 | $355,511 | | tax credit/rebate; property tax abatement |
AMRI Rensselaer, Inc. | Curia Inc. | New York | state | 2008 | $353,143 | | enterprise zone |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2009 | $351,337 | | tax credit/rebate |
Takeda Pharmaceuticals North America, Inc. | Takeda Pharmaceutical | Illinois | state | 2006 | $350,000 | | grant |
Takeda Pharmaceuticals North America, Inc. | Takeda Pharmaceutical | Illinois | state | 2007 | $350,000 | | grant |
ImClone Systems | Eli Lilly | New Jersey | state | 2010 | $350,000 | | tax credit/rebate |
Daiichi Sankyo, Inc. | Daiichi Sankyo | Pennsylvania | state | | $350,000 | | grant |
Albany Molecular Research, Inc. | Curia Inc. | Indiana | state | 2013 | $350,000 | | tax credit/rebate |
CSL Behring | CSL Limited | Pennsylvania | state | | $350,000 | | grant |
Novartis Vaccines & Diagnostics, Inc. | Novartis | North Carolina | state | 2012 | $347,213 | | tax credit/rebate |
Novartis Vaccines & Diagnostics, Inc | Novartis | North Carolina | state | 2014 | $347,000 | | grant |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New Jersey | state | 2011 | $345,900 | | grant |
Celgene | Bristol-Myers Squibb | New Jersey | state | 2005 | $345,800 | | tax credit/rebate |
CSL Behring, LLC | CSL Limited | Pennsylvania | state | 2013 | $345,642 | | tax credit/rebate |
Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | Pennsylvania | state | | $345,000 | | tax credit/rebate |
Hospira, Inc. | Pfizer | North Carolina | state | 2011 | $344,981 | | tax credit/rebate |
ABBOTT VASCULAR, INC. | Abbott Laboratories | California | state | 2014 | $344,534 | | training reimbursement |
Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | Connecticut | state | 2012 | $344,500 | | tax credit/rebate |
Synthes Spine, Inc. | Johnson & Johnson | Pennsylvania | state | 2008 | $344,128 | | tax credit/rebate |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2009 | $343,915 | | tax credit/rebate; property tax abatement |
Novartis Pharmaceuticals Corp. | Novartis | North Carolina | state | 2017 | $343,670 | | tax credit/rebate |
BOEHRINGER INGELHEIM FREMONT INC | Boehringer Ingelheim | California | state | 2019 | $343,449 | | training reimbursement |
Bristol Myers Squibb (Mr. Leon Squibb) | Bristol-Myers Squibb | New York | local | 2003 | $343,428 | | tax credit/rebate; property tax abatement |
CSL Behring, LLC | CSL Limited | Pennsylvania | state | 2012 | $342,911 | | tax credit/rebate |
PBM Covington, LLC | Perrigo | Ohio | state | 2009 | $339,354 | | tax credit/rebate |
CSL Behring | CSL Limited | Pennsylvania | state | | $339,000 | | tax credit/rebate |
CSL Behring | CSL Limited | Pennsylvania | state | 2014 | $339,000 | | tax credit/rebate |
Eli Lilly and Company | Eli Lilly | North Carolina | state | 2013 | $338,906 | | tax credit/rebate |
OSI Pharmaceuticals LLC | Astellas Pharma | New York | local | 2012 | $338,863 | | tax credit/rebate; property tax abatement |
Aventis Pharmaceuticals | Sanofi | Missouri | local | 2007 | $338,637 | | tax increment financing |
Amgen, Inc. | Amgen | Pennsylvania | state | 2009 | $336,279 | | tax credit/rebate |
Bristol-Myers Squibb | Bristol-Myers Squibb | New York | local | 2022 | $336,050 | | tax credit/rebate |
IDEXX Laboratories, Inc. | IDEXX Laboratories | Maine | state | 2010 | $334,454 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2004 | $333,589 | | tax credit/rebate |
GILEAD SCIENCES, INC. | Gilead Sciences | Washington | state | 2017 | $333,444 | | tax credit/rebate |
GILEAD SCIENCES, INC. | Gilead Sciences | Washington | state | 2018 | $333,444 | | tax credit/rebate |
AMRI Rensselaer, Inc. | Curia Inc. | New York | state | 2013 | $333,000 | | enterprise zone |
Bristol Myers Squibb (Mr. Leon Squibb) | Bristol-Myers Squibb | New York | local | 2005 | $327,383 | | tax credit/rebate; property tax abatement |
Steel Forest, LLC | AbbVie | New York | local | 2020 | $326,753 | | tax credit/rebate |
ALLERGAN INC | AbbVie | California | state | 2015 | $325,700 | | training reimbursement |
Eisai, Inc. | Eisai | New Jersey | state | 2005 | $325,500 | | tax credit/rebate |
Regeneron 1CSC Office/Lab Extension | Regeneron Pharmaceuticals | New York | local | 2019 | $322,052 | | tax credit/rebate |
Novozymes North America, Inc. | Novo Holdings A/S | North Carolina | state | 2016 | $321,201 | | tax credit/rebate |
Immunex Corporation | Amgen | Pennsylvania | state | 2013 | $319,819 | | tax credit/rebate |
Gilead Sciences, Inc. | Gilead Sciences | North Carolina | state | 2015 | $319,628 | | tax credit/rebate |
Novartis Vaccines & Diagnostics, Inc. | Novartis | North Carolina | state | 2011 | $318,349 | | tax credit/rebate |
Cambrex Charles City, Inc. | Cambrex | Iowa | state | 2013 | $318,203 | | training reimbursement |
OSI Pharmaceuticals/(OSI) Ardsley | Astellas Pharma | New York | local | 2009 | $317,597 | | tax credit/rebate; property tax abatement |
Amneal Pharmaceutical of NY, LLC | Amneal Pharmaceuticals | New York | state | 2011 | $316,824 | | enterprise zone |
GlaxoSmithKline Biologicals North America | GlaxoSmithKline | Pennsylvania | state | | $316,181 | | training reimbursement |
PFIZER, INC. | Pfizer | Missouri | state | 2000 | $315,055 | | tax credit/rebate |